

Accepted Manuscript



Triple Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease

Renato D. Lopes, MD, MHS, PhD, Meena Rao, MD, DaJuanicia N. Simon, MS, Laine Thomas, PhD, Jack Ansell, MD, Gregg C. Fonarow, MD, Bernard J. Gersh, MB, ChB, DPhil, Alan S. Go, MD, Elaine M. Hylek, MD, MPH, Peter Kowey, MD, Jonathan P. Piccini, MD, MHS, Daniel E. Singer, MD, Paul Chang, MD, Eric D. Peterson, MD, MPH, Kenneth W. Mahaffey, MD

PII: S0002-9343(16)30025-0

DOI: [10.1016/j.amjmed.2015.12.026](https://doi.org/10.1016/j.amjmed.2015.12.026)

Reference: AJM 13329

To appear in: *The American Journal of Medicine*

Received Date: 16 November 2015

Revised Date: 14 December 2015

Accepted Date: 15 December 2015

Please cite this article as: Lopes RD, Rao M, Simon DN, Thomas L, Ansell J, Fonarow GC, Gersh BJ, Go AS, Hylek EM, Kowey P, Piccini JP, Singer DE, Chang P, Peterson ED, Mahaffey KW, Triple Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease, *The American Journal of Medicine* (2016), doi: 10.1016/j.amjmed.2015.12.026.

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Triple Versus Dual Antithrombotic Therapy in Patients With Atrial Fibrillation and Coronary Artery Disease

Renato D. Lopes, MD, MHS, PhD,^a Meena Rao, MD,^a DaJuanicia N. Simon, MS,^a Laine Thomas, PhD,^a Jack Ansell, MD,^b Gregg C. Fonarow, MD,^c Bernard J. Gersh, MB, ChB, DPhil,^d Alan S. Go, MD,^e Elaine M. Hylek, MD, MPH,^f Peter Kowey, MD,^g Jonathan P. Piccini, MD, MHS,^a Daniel E. Singer, MD,^h Paul Chang, MD,ⁱ Eric D. Peterson, MD, MPH,^a Kenneth W. Mahaffey, MD^j

^aDuke Clinical Research Institute, Duke University School of Medicine, Durham, NC; ^bHofstra North Shore/LIJ School of Medicine, New York, NY; ^cUCLA School of Medicine, Los Angeles, CA; ^dMayo Clinic College of Medicine, Rochester, MN; ^eKaiser Permanente, Oakland, CA; ^fBoston University School of Medicine, Boston, MA; ^gLankenau Institute for Medical Research, Wynnewood, PA; ^hHarvard Medical School and Massachusetts General Hospital, Boston, MA; ⁱJanssen Pharmaceuticals, Raritan, NJ; ^jStanford University School of Medicine, Stanford, CA.

Running title: Triple Versus Dual Antithrombotic Therapy

Address for correspondence: Dr. Renato D. Lopes, Duke Clinical Research Institute, Box 3850, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705; E-mail: renato.lopes@duke.edu; phone: 919-668-8241; fax: 919-668-7056.

Funding: The ORBIT-AF registry is sponsored by Janssen Scientific Affairs, Raritan, NJ. The authors are solely responsible for the design and conduct of this study, all study analyses, the drafting and editing of the paper, and its final contents.

Conflict of Interest: R.D.L. reports consulting fees and research grants from Bristol-Myers Squibb, research grants from GlaxoSmithKline, and consulting fees from Boehringer-Ingelheim, Bayer, and Pfizer. J.A. reports consultant/advisory board fees from Bristol Myers Squibb, Pfizer, Janssen Pharmaceuticals, Daiichi Sankyo, Boehringer-Ingelheim, and Alere. G.C.F. reports consultant/advisory board fees from Ortho McNeil. B.J.G. reports DSMB/advisory board fees

Download English Version:

<https://daneshyari.com/en/article/5877476>

Download Persian Version:

<https://daneshyari.com/article/5877476>

[Daneshyari.com](https://daneshyari.com)